Bilirubin Blood Test Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)
The global Bilirubin Blood Test Market size is forecast to increase from $1.68 Billion in 2026 to $2.76 Billion in 2034 at a CAGR of 6.4% between 2026 and 2034.
The Bilirubin Blood Test market report provides detailed analysis and outlook of Bilirubin Blood Test segments including By Test Type (Total Bilirubin Test, Direct, Indirect ), By Technology (Colorimetric Assays, Spectrophotometry, Dry Chemistry Analyzers), By End-User (Hospitals, Diagnostic Laboratories, Clinics, Blood Banks) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Bilirubin Blood Test Industry Overview
Expanding Importance of Bilirubin Testing in Liver Health Management
The bilirubin blood test industry is playing an increasingly important role in modern diagnostics as healthcare providers focus on early detection and monitoring of liver diseases, biliary disorders, and neonatal jaundice. Bilirubin testing remains a fundamental component of liver function assessment and is widely used to evaluate hepatic health, hemolytic conditions, and bile duct abnormalities. Growing awareness of chronic liver diseases, increasing prevalence of metabolic disorders, and rising demand for preventive healthcare services are driving broader utilization of bilirubin testing across hospitals, diagnostic laboratories, primary care clinics, and outpatient healthcare settings.
Portable and Point-of-Care Technologies Transforming Bilirubin Assessment
A major trend reshaping the bilirubin blood test market is the rapid adoption of portable, non-invasive, and point-of-care diagnostic technologies. These advanced testing solutions enable bilirubin assessment significantly faster than traditional laboratory-based quantification methods, with some systems delivering results up to sixty times more rapidly. Such capabilities are particularly valuable in neonatal jaundice screening, emergency care environments, and urgent liver function evaluations where rapid clinical decision-making is essential. The increasing availability of portable bilirubin testing devices is improving accessibility, reducing diagnostic delays, and supporting more timely patient management across diverse healthcare settings.
Routine Liver Health Screening Expanding Testing Volumes
The growing emphasis on preventive healthcare and chronic disease management is driving increased demand for bilirubin testing beyond specialized hospital environments. Healthcare providers are placing greater focus on routine liver health assessment, particularly among aging populations and individuals affected by metabolic disorders or alcohol-related liver disease. As a result, automated serum bilirubin testing is becoming more widely utilized in primary care settings, community health centers, and outpatient clinics. This shift is expanding the role of bilirubin testing as a routine diagnostic tool for early identification of liver dysfunction and ongoing monitoring of at-risk patient populations.
Digital Health Integration Enhancing Diagnostic Workflows
Diagnostic companies are increasingly collaborating with healthcare technology providers to integrate bilirubin monitoring solutions into broader digital health ecosystems. These partnerships focus on connecting bilirubin testing platforms with cloud-based patient management systems and digital healthcare infrastructure. The integration of laboratory data, remote monitoring capabilities, and electronic health records enables more streamlined liver disease diagnosis and patient management. Digital connectivity is improving data accessibility for clinicians, supporting longitudinal patient monitoring, and enhancing care coordination across healthcare networks. As healthcare systems continue to adopt connected diagnostic solutions, bilirubin testing is becoming an integral component of data-driven liver disease management strategies.
Bilirubin Blood Test Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Bilirubin Blood Test market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Roche Diagnostics, Danaher Corporation (Beckman Coulter), Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, Randox Laboratories, Horiba Medical, Mindray Medical International, Ortho Clinical Diagnostics (QuidelOrtho). The Bilirubin Blood Test market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Bilirubin Blood Test industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
-
Growth Bilirubin Blood Test Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
-
Market Trends, Drivers, Potential Opportunities, and Challenges faced by Bilirubin Blood Test companies
-
Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
-
Detailed SWOT Analysis of global and regional Bilirubin Blood Test markets
-
Competitive analysis including business description, product analysis, and financial profiles
-
Key country specific analysis detailing key factors shaping the short-term and long-term outlook
-
Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Bilirubin Blood Test Market Competitive Benchmarking and Company Analysis
Leading companies in Bilirubin Blood Test industry include- Roche Diagnostics, Danaher Corporation (Beckman Coulter), Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, Randox Laboratories, Horiba Medical, Mindray Medical International, Ortho Clinical Diagnostics (QuidelOrtho). The Bilirubin Blood Test market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Bilirubin Blood Test Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Bilirubin Blood Test market remains one of the strongest-performing segments in the country.
The US Bilirubin Blood Test Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Bilirubin Blood Test market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Bilirubin Blood Test industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Bilirubin Blood Test markets
Canada's strong Bilirubin Blood Test sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Bilirubin Blood Test market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Bilirubin Blood Test Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Bilirubin Blood Test market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Bilirubin Blood Test population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Bilirubin Blood Test industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Bilirubin Blood Test market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Bilirubin Blood Test sales through 2034
France Bilirubin Blood Test companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Bilirubin Blood Test Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Bilirubin Blood Test distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Bilirubin Blood Test Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Bilirubin Blood Test market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Bilirubin Blood Test industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Bilirubin Blood Test industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Bilirubin Blood Test Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Bilirubin Blood Test market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Bilirubin Blood Test market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Bilirubin Blood Test Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Bilirubin Blood Test Market Segmentation
By Test Type
Total Bilirubin Test
Direct
Indirect
By Technology
Colorimetric Assays
Spectrophotometry
Dry Chemistry Analyzers
By End-User
Hospitals
Diagnostic Laboratories
Clinics
Blood Banks
Top Companies in Bilirubin Blood Test Industry
Roche Diagnostics
Danaher Corporation (Beckman Coulter)
Abbott Laboratories
Siemens Healthineers
Thermo Fisher Scientific
Bio-Rad Laboratories
Randox Laboratories
Horiba Medical
Mindray Medical International
Ortho Clinical Diagnostics (QuidelOrtho)
Countries Included
-
North America- US, Canada, Mexico
-
Europe- Germany, France, UK, Spain, Italy, Nordics, Others
-
Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
-
Latin America- Brazil, Argentina, Others
-
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Latest Market Updates In Healthcare
Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.
By Test Type
Total Bilirubin Test
Direct
Indirect
By Technology
Colorimetric Assays
Spectrophotometry
Dry Chemistry Analyzers
By End-User
Hospitals
Diagnostic Laboratories
Clinics
Blood Banks